<?xml version="1.0" encoding="UTF-8"?>
<table xmlns="http://www.w3.org/1999/xhtml">
 <caption class="caption">
  <label class="label">TABLE 2</label>
  <p class="p" xmlns="">Checklist of Recommendations: Fatty Acid Best Practices, organized in order of appearance and grouped according to the major headings in the text 
   <sup class="sup">
    <xref ref-type="table-fn" rid="tb2fn1" class="xref">1</xref>
   </sup>
  </p>
 </caption>
 <tbody class="tbody">
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Fatty acid trials. The independent variable</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 1) Treatment fatty acids. All fatty acids in the food or supplements relevant to the issue under investigation must be analyzed and defined.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 2) Sampled pool. The rationale for the choice of blood pool should be stated and justified with respect to the biological research question, taking into account logistic issues with respect to study design.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 3) Intervention length. Intervention length should be rationalized based on the hypothesis.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 4) Control composition. Control (comparator/placebo) doses should be chosen to be neutral with respect to the outcome, considering the known metabolism and concentrations of dietary fat with respect to the hypothesis and the study population.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 5) Biological responsiveness. The responsiveness of the target fatty acid pools should be considered with respect to the chosen intervention doses and duration.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 6) Fatty acid dynamics. Dietary fatty acid exposure and implications for well-established principles of fatty acid metabolism must be taken into account for interpreting the diet-blood relationship.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 7) Data analysis principles. All fatty acid intervention trials should report ≥1 measure of fatty acid concentration within a specified biological compartment so as to enable analysis on both an ITT and a PP basis.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 8) Fatty acid ranges. Intervention-based changes in circulating fatty acids should be compared with previous literature reports to establish that they fall into expected ranges.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Sample collection procedures</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 9) Population and blood pool ranges. Levels of particular or summed fatty acids, such as n–3 fatty acids, are modified in specific populations and/or blood pools. These changes should be taken into account when interpreting the results.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 10) Relevant physiologic state. Reports should outline medical, physiologic and behavioral conditions that may influence fatty acid target outcomes and discuss steps taken to minimize their effects.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Sample preparation and analysis</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 11) Sample integrity during storage. Details of sampling and storage should be reported, including timing between sampling and analysis, storage temperature, duration, and any antioxidant/protectant used.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 12) Fit-for-purpose sample preparation. The method used to extract fatty acids and derivatize fatty acids to FAME should be explicitly stated and reference to the original studies of their use should be cited.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 13) Analytical chemical fidelity. Methods should be reported in sufficient detail to unequivocally establish fatty acid identity and resolution.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Reporting</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 14) Fatty acid units. The rationale for primary reporting of fatty acid profile or absolute fatty acid concentration should be reported with respect to the hypotheses.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 15) Data interconvertibility. Regardless of the choice of primary reporting method, all reports should include sufficient data to convert relative to absolute concentrations and vice versa.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 16) Fatty acid base. The base of total fatty acids used in profile calculations should be specified, and the range of fatty acids marked in Table 1, particularly those in category A, should be reported to enable secondary calculations and interpretation.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 17) Relative response calibration. In practice, response factors should be evaluated daily.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 18) Internal standards. The rationale and procedure for IS should be reported, when used.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 19) Fatty acid identity. The identity of all FAME must be established for accurate analysis, and the methods used must be reported in the paper or 
    <xref ref-type="supplementary-material" rid="sup1" class="xref">supplementary materials</xref>. 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 20) Comprehensive analysis. When LC/MS is necessary, panels of fatty acids encompassing at least the same range that are routine in GC should be analyzed qualitatively and quantitatively.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 21) Minimal detectable limits. Limits of detection or lower limits of quantification should be reported when fatty acids are not detected or quantified.</td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td"> 22) Quality control. Reports should specify the QC procedures used for sample analyses.</td>
  </tr>
 </tbody>
 <tfoot>
  <p charset="fn" id="tb2fn1" class="fn">
   <p class="p" xmlns="">
    <sup class="sup">1</sup>FAME, fatty acid methyl ester; IS, internal standards; ITT, intent-to-treat; LC, liquid chromatography; MS, mass spectrometry; PP, per protocol; QC, quality control. 
   </p>
  </p>
 </tfoot>
</table>
